Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT03138538 Terminated - Clinical trials for Advanced Solid Tumors

M8891 First in Human in Solid Tumors

M8891
Start date: August 8, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study was to determine the maximum tolerated dose (MTD), safety, tolerability, Pharmacokinetic (PK), pharmacodynamic and clinical activity of M8891 as single agent in participants with advanced solid tumors in Part 1.

NCT ID: NCT03134638 Terminated - Breast Cancer Clinical Trials

A Study of SY-1365 in Adult Patients With Advanced Solid Tumors

Start date: May 12, 2017
Phase: Phase 1
Study type: Interventional

This study consists of two parts. Part 1 is a dose-escalation/safety evaluation to provisionally identify a dose and regimen of SY-1365 for further evaluation in Part 2. Following the identification of a recommended dose and regimen from Part 1, the study entered Part 2 to further evaluate safety and the antitumor activity of SY-1365 in patients with select solid tumors, and to confirm target engagement and downstream pathway impact in patients with any solid tumor histology.

NCT ID: NCT03133247 Completed - Clinical trials for Advanced Solid Tumors

A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients

Start date: June 1, 2017
Phase: Phase 1
Study type: Interventional

In many types of human tumors, PD-L1 is highly expressed. Such high expression has often been associated with poor prognosis in cancer patients. SHR-1316 is a humanized IgG4 monoclonal antibody that binds specifically to human PD-L1.

NCT ID: NCT03117101 Completed - Clinical trials for Advanced Solid Tumors

Study of the AL3810 in the Treatment of Advanced Solid Tumor

Start date: March 2014
Phase: Phase 1
Study type: Interventional

This was a monocentric, open label, non-randomised, non-comparative, dose-finding phase I study

NCT ID: NCT03113188 Completed - Clinical trials for Advanced Solid Tumors

CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

Start date: October 25, 2017
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, phase 1b study of CBP501/cisplatin/nivolumab combination administered once every 21 days to patients with advanced solid tumors.

NCT ID: NCT03089645 Completed - Clinical trials for Advanced Solid Tumors

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

Start date: March 21, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics and Immunogenicity of Medi5083 alone or in combination with Durvalumab,Tremelimumab, and/or Docetaxel in adult subjects with advanced solid tumors.

NCT ID: NCT03082209 Completed - Cancer Clinical Trials

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

Start date: March 20, 2017
Phase: Phase 1
Study type: Interventional

This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously-treated solid tumors or hematologic malignancies. Only chemotherapy combination (ABBV-621 + FOLFIRI) enrolling participants with RAS-mutant CRC who have received one prior line of therapy is open for enrollment.

NCT ID: NCT03077607 Completed - Clinical trials for Advanced Solid Tumors

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

Start date: November 7, 2016
Phase: Phase 1
Study type: Interventional

This is a study in patients with advanced solid tumors for the investigation of P-gp inhibition and induction on the PK of talazoparib.

NCT ID: NCT03070548 Completed - Clinical trials for Advanced Solid Tumors

A Study of Talazoparib in Patients With Advanced Solid Tumors

Start date: September 2016
Phase: Phase 1
Study type: Interventional

This study will evaluate the mass balance of talazoparib after a single dose of talazoparib.

NCT ID: NCT03065023 Terminated - Clinical trials for Advanced Solid Tumors

Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)

Start date: April 25, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II multicenter, first-in-human open-label, dose escalation study to evaluate the safety, tolerability, and anti-tumor activity of intratumoral (IT)/intralesional (IL) injections of MK-4621 (RGT100) in adult participants with selected advanced or recurrent tumors.